Adachi Takeya, Kainuma Keigo, Asano Koichiro, Amagai Masayuki, Arai Hiroyuki, Ishii Ken J, Ito Komei, Uchio Eiichi, Ebisawa Motohiro, Okano Mitsuhiro, Kabashima Kenji, Kondo Kenji, Konno Satoshi, Saeki Hidehisa, Sonobe Mariko, Nagao Mizuho, Hizawa Nobuyuki, Fukushima Atsuki, Fujieda Shigeharu, Matsumoto Kenji, Morita Hideaki, Yamamoto Kazuhiko, Yoshimoto Akemi, Tamari Mayumi
Japan Agency for Medical Research and Development (AMED), Tokyo, Japan; International Human Frontier Science Program Organization (HFSPO), Strasbourg, France; CNRS UPR 3572, Institut de Biologie Moléculaire et Cellulaire (IBMC), Université de Strasbourg, Strasbourg, France.
Institute for Clinical Research, National Hospital Organization, Mie National Hospital, Mie, Japan.
Allergol Int. 2020 Oct;69(4):561-570. doi: 10.1016/j.alit.2020.04.006. Epub 2020 Jun 27.
Strategic Outlook toward 2030: Japan's Research for Allergy and Immunology (Strategy 2030) is the national research strategy based on Japan's Basic Law on Measures Against Allergic Diseases, a first of its kind worldwide. This strategy was established by a multi-disciplinary committee consisting of administrators of the Ministry of Health, Labour and Welfare of Japan, young and senior experts from various research societies and associations, and representatives of patient and public groups. Whereas the issues of transition, integration, and international collaboration have yet to be solved in this research realm in Japan, identification of unmet needs, digitization of information and transparent procedures, and strategic planning for complex problems (a process dubbed MIERUKA by the Toyota Way) are crucial to share and tackle the same vision and goals. The committee developed three specific actions focusing on preemptive treatment, interdisciplinarity and internationality, and life stage. The real success of Strategy 2030 is made by the spontaneous contributions of doctors, dentists, veterinarians, and other medical professionals; basic and clinical research scientists, research supporters, and pharmaceutical/medical device companies; manufacturers of food, healthcare, and home appliances; and patients, their families, and the public. The hope is to establish a stable society in which people can live long, healthy lives, as free as possible from allergic and immunological diseases, at each individual life stage. This article is based on a Japanese review first reported in Arerugi, introduces the developmental process and details of Strategy 2030.
《2030年战略展望：日本的过敏与免疫学研究（2030战略）》是基于日本《过敏性疾病对策基本法》制定的国家研究战略，这在全球尚属首次。该战略由一个多学科委员会制定，成员包括日本厚生劳动省的管理人员、各研究学会和协会的青年及资深专家，以及患者和公众团体的代表。尽管日本在这一研究领域的转型、整合和国际合作问题仍有待解决，但识别未满足的需求、信息数字化和程序透明化，以及针对复杂问题的战略规划（丰田生产方式中称为“可视化管理”的过程）对于分享和应对共同的愿景与目标至关重要。委员会制定了三项具体行动，重点关注预防性治疗、跨学科与国际化以及生命阶段。2030战略的真正成功离不开医生、牙医、兽医及其他医疗专业人员；基础和临床研究科学家、研究支持者以及制药/医疗器械公司；食品、医疗保健和家电制造商；以及患者、其家人和公众的自发贡献。希望建立一个稳定的社会，让人们在每个生命阶段都能尽可能远离过敏性和免疫性疾病，健康长寿地生活。本文基于首次发表于《过敏》杂志的一篇日文综述，介绍了2030战略的制定过程和详细内容。
